Large-Scale DPD Testing Should Be More Than an Option.

Marie-Christine Etienne-Grimaldi Bernard Royer Manon Launay Antonin Schmitt Fabienne Thomas Joseph Ciccolini

JCO Oncol Pract

Marie-Christine Etienne-Grimaldi, PhD, PharmD, Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, France; Bernard Royer, PhD, PharmD, Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon and Univ. Franche-Comté, INSERM, EFS BFC, UMR1098, Besançon, France; Manon Launay, PhD, PharmD, Institut Curie, Service de Pharmacologie, Saint-Cloud, France; Antonin Schmitt, PhD, PharmD, Pharmacy Department, Centre Georges-François Leclerc, Dijon and INSERM U1231, University of Burgundy Franche-Comté, Dijon, France; Fabienne Thomas, PhD, PharmD, Oncopole Claudius Regaud, Institut Universitaire du Cancer and CRCT, University of Toulouse, Inserm, Toulouse, France; and Joseph Ciccolini, PhD, PharmD, COMPO Centre de Recherche en Cancérologie de Marseille Inserm U1068 and University Hospital of Marseille, Marseille, France.

Published: December 2024

Download full-text PDF	Source
http://dx.doi.org/10.1200/OP-24-00464	DOI Listing

Publication Analysis

Top Keywords

large-scale dpd

dpd testing

testing option

large-scale

testing

option

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!